[First echinocandin on the market. New type of antifungal against Aspergillus & Co].
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D000077336:Caspofungin; D017277:Drug Approval; D054714:Echinocandins; D005060:Europe; D006801:Humans; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin